Longitudinal PET/CT imaging with iodine (¹²⁴I) evuzamitide reveals organ response to plasma cell immunotherapy in a patient with AL amyloidosis

"Longitudinal PET/CT imaging with iodine (124I) evuzamitide reveals organ response to plasma cell immunotherapy in a patient with AL amyloidosis." Amyloid, ahead-of-print(ahead-of-print), pp. 1–2

Disclosure statement

EBM, AS and SJK are founders and owners of Attralus Inc. JSW is interim CSO, founder and owner of Attralus Inc. SG is COO, founder and owner of Attralus Inc, which holds the licence for ¹²⁴I-p5 + 14. JSW and SJK are inventors and have patent rights in peptide p5 + 14. Attralus has licenced the ¹²⁴I-p5 + 14 patent but was not involved in the discovery of the peptide nor the conception or design of this study.

Additional information

Funding

This study was supported with services from the National Heart Lung and Blood Institute, National Institutes of Health, Department of Health and Human Services, through the Science Moving TowArds Research Translation and Therapy (SMARTT) program via the following contracts: HHSN268201600011C, HHSN268201600012C and HHSN268201600014C. Clinical studies were funded in part by Attralus, Inc and by contributions to the Amyloidosis and Cancer Theranostics Gift Fund (including CMC/Gerdau, Knoxville) that funded the study. We greatly appreciate the support of all the patients and their families who donated their time and resources to participate in the imaging studies.